Table 2. Median best-corrected visual acuity (ETDRS letter) during the 1-year follow-up study.
| Baseline | 4 Months | 8 Months | 12 Months | |
|---|---|---|---|---|
| All patients, median ETDRS letter (95% CI) | 65 (60–70) | 65 (61–72, p: 0.08) | 66 (60–72, p: 0.87) | 67 (60–70, p: 0.24) |
| PRN regimen | 63 (52–71) | 60 (55–68, p: 0.54)a | 60 (52–68, p: 0.54)a | 60 (54–64, p: 0.91)a |
| vs baseline 0.92b | vs baseline 0.33b | |||
| Fixed regimen group (Loading phase+2q8) | 68 (60–72) | 71 (64–77, p: 0.02)a | 74 (63–78, p: 0.75)a | 71 (65–79, p: 0.73)a |
| vs baseline 0.0.006b | vs baseline 0.008b | |||
| PRN group vs fixed regimen group | (p: 0.31) | (p: 0.03) | (p: 0.02) | (p: 0.01) |
Abbreviations: BCVA, best-corrected visual acuity; fixed regimen, loading phase+bimonthly injections; PRN, pro re nata strategy.
a
Compared previous follow-up visit.
b
Compared with baseline value.
The median BCVA showed stabilization in the PRN group over the whole study period; a statistically significant improvement in BCVA was recorded at 4-month examination in the fixed regimen group, which was preserved on subsequent visits at 8 and 12 months.